July 8, 2021 – SAN DIEGO – Lysulin, Inc. announced today another patent approval for their flagship product Lysulin®, a first-in-class nutritional supplement formulated for people with Type 2 diabetes and prediabetes. Lysulin® provides a breakthrough approach for blood glucose management in an all-natural product available over the counter, without a prescription, at low cost.
Lysulin’s® approved patent is the sixth patent secured for the company, for its method of improving beta-cell function with a supplement.
Dr. John F. Burd, CEO of Lysulin, Inc., says, “We are pleased to have another patent covering the use of Lysulin® to improve diabetes management. Lysulin® is the only product that targets the cause of insulin resistance and type 2 diabetes and proven in published clinical studies.”
Dr. Burd was the founder and first CEO of DexCom and is renowned for his work in the medical and biotechnology field. He was inducted into the American Association of Clinical Chemistry (AACC) Hall of Fame in 2005 after winning the Ullman prize for innovation in clinical chemistry.
Lysulin is available without a prescription and can be purchased at http://www.lysulin.com, Amazon and Walmart.com.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or any prevent disease.
Media Contact: Michelle Stansbury